Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC)

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|15|3|243-255

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.15, Iss.3, 2015-05, pp. : 243-255

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC)

By Mitsogiannis Iraklis C   Skolarikos Andreas   Deliveliotis Charalambos  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 3, 2009-02 ,pp. : 493-501

Informa Healthcare

Access to resources Recommend Favorite

Androgen Metabolic Pathway Involved in Current and Emerging Treatment for Men with Castration Resistant Prostate Cancer: Intraprostatic Androgens as Therapeutic Targets and Endocrinological Biomarkers

By  

Current Drug Targets, Vol. 15, Iss. 13, 2014-12 ,pp. : 1215-1224

Bentham Science Publishers

Access to resources Recommend Favorite

Castration Resistant Prostate Cancer: From Emerging Molecular Pathways to Targeted Therapeutic Approaches

By  

Clinical Cancer Drugs, Vol. 1, Iss. 1, 2014-01 ,pp. : 11-27

Bentham Science Publishers

Access to resources Recommend Favorite

Castration Resistant Prostate Cancer: From Emerging Molecular Pathways to Targeted Therapeutic Approaches

By  

Clinical Cancer Drugs, Vol. 1, Iss. 1, 2013-12 ,pp. : 11-27

Bentham Science Publishers

Access to resources Recommend Favorite

Cholesterol as a Potential Target for Castration-Resistant Prostate Cancer

By Twiddy Alexis   Leon Carlos   Wasan Kishor  

Pharmaceutical Research, Vol. 28, Iss. 3, 2011-03 ,pp. : 423-437

Springer Publishing Company

Access to resources Recommend Favorite